Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06376916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Study acronym: ATRIUM
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 1 of 6 entries
  2. Primary completion date: Dec 2025 to Dec 2026v8
  3. Re-verified, no change to tracked fieldsv7
  4. Start date: May 8, 2024 to Oct 7, 2024v6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date changed from estimate of Jun 2024 to May 8, 2024v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 2024 to Jun 2024
    • Site details revised
    v3
  3. Secondary endpoints revised (6)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Trial Details
NCT Number NCT06376916
Lead Sponsor Wake Forest University Health Sciences
Conditions
(from sponsor)		 Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Related terms Atrial Fibrillation
Enrollment 153 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov